Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Monoclonal antibody 3F8 (Primary) ; Interleukin-2
- Indications Neuroblastoma; Solid tumours
- Focus Adverse reactions
- 27 May 2021 Biomarkers information updated
- 05 Oct 2013 Planned End Date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 05 Oct 2013 Last checked against ClinicalTrials.gov record.